Intratumoural thymidylate synthase and dihydropyrimidine dehydrogenase activities are good predictors of 5-fluorouracil sensitivity in colorectal cancer

Journal of International Medical Research

Volumn 31, Issue 3, 2003, Pages 181-187

  Ishibiki, Y ^a   Kitajima, M ^a   Sakamoto, K ^a   Tomiki, Y ^a   Sakamoto, S ^a   Kamano, T ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 Fluorouracil; Colorectal cancer; Dehydrogenase; Dihydropyrimidine; Thymidylate synthase

Indexed keywords

5 CHLOROURACIL DERIVATIVE; ANTINEOPLASTIC ANTIMETABOLITE; BIOLOGICAL MARKER; CYCLOOXYGENASE 2; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MUTANT PROTEIN; NITRIC OXIDE SYNTHASE; PROTEIN P21; PROTEIN P53; PYRIMIDINE NUCLEOSIDE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL TUMOR; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYMOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; METABOLISM; PREDICTION AND FORECASTING; PROTEIN EXPRESSION; WILD TYPE;

EID: 0038159420     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000303100303     Document Type: Article

References (14)

1. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6: 1322-127.
2. Lenz H-J, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, et al: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 1998; 4: 1243-1250.
3. Aschele C, Debernardis D, Bandelloni R, Cascinu S, Catalano V, Giordani P, et al: Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. Ann Oncol 2002; 13: 1882-1892.
4. Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renee N, et al: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994; 30: 1517-1522.
5. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, et al: Response to fluorouracil therapy in cancer patients. The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13: 1663-1670.
6. Johnston PG, Lenz H-J, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, et al: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1407-1412.
7. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, et al: Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res 2000; 91: 105-112.
8. Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, et al: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998; 4: 2371-2376.
9. Diasio RB, Beavers TL, Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase biochemical bases for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988; 81: 47-51.
10. Eda H, Fujimoto K, Watanabe S, Ura M, Hino A, Tanaka Y, et al: Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 1993; 32: 333-338.
11. Kobayashi H, Tanisaka K, Doi O, Kodama K, Higashiyama M, Nakagawa H, et al: An in vitro chemosensitivity test for solid human tumors using collagen gel droplet embedded cultures. Int J Oncol 1997; 11: 449-455.
12. Haraguchi M, Furukawa T, Sumizawa T, Akiyama S: Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites. Cancer Res 1993; 53: 5680-5682.
13. Patterson AV, Zhang H, Moghadddam A, Bicknell R, Talbot DC, Stratford IJ, et al: Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer 1995; 72: 669-675.
14. Banerjee D, Gorlick R, Liefshitz A, Danenberg K, Danenberg PC, Danenberg PV, et al: Levels of E2F-1 expession are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase. Cancer Res 2000; 60: 2365-2367.